TraceLink operates a track-and-trace network platform that connects the life sciences supply chain and provides real-time information-sharing to support better patient outcomes. Its network connects over 270,000 pharmaceutical companies, CMOs, wholesale distributors, 3PLs, repackagers, hospitals and pharmacies worldwide and serves a customer base of 930+ pharmaceutical manufacturers and related organizations. The company plans to use new funding to accelerate digitalization of the global pharmaceutical supply chain through deeper integration of real-time information sharing. It also intends to expand into adjacent application areas including supplier collaboration, patient communities, personalized medicine, predictive care and gene therapies. TraceLink will reinforce its R&D and Services organizations to better support its customers. Founded in 2009 and led by president and CEO Shabbir Dahod, the company has raised $93M in the most recent round, bringing total funding to $167M. TraceLink provides the Life Sciences Cloud, a suite of AWS-integrated SaaS applications that enable pharmaceutical manufacturers, distributors, and dispensers to comply with country-specific track-and-trace requirements across the supply chain. The software is designed to secure drug supply chains and reduce counterfeit medicines, which the company says cause hundreds of thousands of deaths annually and $75 billion in lost industry revenue. TraceLink was founded in 2009 and has positioned its platform around the compliance timeline set by the 2013 DSCSA, which gives the industry time to achieve unit-level traceability. The company reports it has continued to surpass its growth goals. Management plans to accelerate adoption of the platform and extend its leadership across the global market. Financially, TraceLink recently closed a significant institutional financing to support that expansion. TraceLink provides the TraceLink Life Sciences Cloud, an Amazon AWS-based application platform that delivers complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient across the life sciences supply network. The platform serves drug manufacturers, distributors, repackagers and dispensers and is intended to help protect patients from counterfeit drugs. TraceLink currently serves over 100 signed customers, including 15 of the top-20 global pharma companies. Led by president and CEO Shabbir Dahod, the company plans to use new funding to further invest in product development to support growing country-specific regulations. It also intends to increase sales, services and marketing presence across North America, Latin America, EMEA and Asia Pacific. The company is based in Wakefield, MA. TraceLink provides an Amazon AWS-based cloud application platform enabling complete global connectivity, visibility and traceability of pharmaceuticals from raw materials to patient. Its solutions combine serialization, government reporting, network connectivity and transaction monitoring tools to ensure regulatory compliance, monitor drug quality and reach global markets. TraceLink serves customers across the life sciences supply chain, including pharmaceutical companies, CMO/CPOs, 3PLs, wholesale distributors and pharmacies. Led by President and CEO Shabbir Dahod, the Wakefield, MA-based company raised $5.5M in growth capital. The round was led by FirstMark Capital. The company intends to use the funds to accelerate development and deployment of its solutions.

Total raised

$170M

Funding rounds

4

Latest round

Series D

Latest activity

Aug 2018